Treatment of enterococcal periprosthetic joint infections (PJI) is challenging due to heterogeneous pathogenesis, non-standardized management strategies and lack of biofilm-active antibiotics. Previous studies report treatment success from 50–76%. We evaluated the characteristics and outcome of enterococcal PJI, in particular the influence of antimicrobial treatment regimens. Consecutive patients with enterococcal PJI treated at two specialized orthopaedic institutions were retrospectively included from 2010 to 2017. PJI was defined by the proposed European Bone and Joint Infection Society (EBJIS) criteria. Adequate antimicrobial treatment was considered when the antibiotic was appropiate for the treatment of enterococcal bone infections (activity, dose, oral bioavailability, bone penetration). The treatment success (defined as no relapse of enteroccal infection) and clinical success(i.e. infection-free status) was evaluated and compared using Fishers exact test.Aim
Method
The incidence of hematogenous periprosthetic joint infections (hPJI) is unknown and the cases probably largely underreported. Unrecognized and untreated primary infectious foci may cause continuous bacteremia, further spread of microorganisms and thus treatment failure or relapse of infection. This study aimed at improving knowledge about primary foci and microbiological characteristics of this entity to establish preventive measures and improve diagnostic and therapeutic strategies to counteract hPJI. We retrospectively analysed all consecutive patients with hPJI, who were treated at our institution from January 2010 until December 2016. Diagnosis of PJI was established if 1 of the following criteria applied:(i) macroscopic purulence, (ii) presence of sinus tract, (iii) positive cytology of joint aspirate (>2000 leukocytes/μl or >70% granulocytes), (iv) significant microbial growth in synovial fluid, periprosthetic tissue or sonication culture of retrieved prosthesis components, (v) positive histopathology. PJI was classified as hematogenous if the following criteria were fulfilled additionally: (1) onset of symptoms more than 1 month after arthroplasty AND (2) i) isolation of the same organism in blood cultures OR ii) evidence of a distant infectious focus consistent with the pathogen.Aim
Method
Periprosthetic joint infections (PJI), caused by pathogens, for which no biofilm-active antibiotics are available, are often referred to as difficult-to-treat (DTT). It is unclear whether DTT PJI has worse outcome due to unavailability of biofilm-active antibiotics. We evaluated the outcome of DTT and non-DTT PJI managed according to a standardized treatment regimen. Patients with hip and knee PJI from 2013 to 2015 were prospectively included and followed-up for ≥2 years. DTT PJI was defined as growth of microorganism(s) resistant to biofilm-active antibiotics. The Kaplan-Meier survival analysis was used to compare the probability of infection-free survival between DTT and non-DTT PJI.Background
Methods
